RAF1 and neoplasm: In a groundbreaking study, sorafenib, a multiple-target tyrosine kinase inhibitor (TKI) exhibited antiangiogenesis and antiproliferation effects and extended total median survival in advanced HCC patients.5 Sorafenib suppresses tumor cell proliferation by inhibiting Raf-1, B-Raf, and kinase activity in the Ras/Raf/MEK/ERK signaling pathways.